Sign in Subscribe
Cancer

Roche's Lunsumio-Polivy Combination Shows Positive Results in Large B-Cell Lymphoma

Strategic Insights

— 2 min read

A recent phase 3 study presented at the International Conference on Malignant Lymphoma has demonstrated the potential of combining the CD20xCD3 bispecific Lunsumio and the CD79b-directed ADC Polivy in treating large B-cell lymphoma (LBCL). The Lunsumio-Polivy regimen showed a significant reduction in the risk of progression or death, compared to the traditional R-GemOx regimen. While the results are promising, the trial's geographic representation might raise concerns for Roche with the FDA.

Key Takeaways:

  • The Lunsumio-Polivy regimen demonstrated a 59% reduction in the risk of progression or death versus the R-GemOx regimen in patients with previously treated LBCL.
  • The median progression-free survival was 11.5 months for Lunsumio-Polivy, compared to 3.8 months for R-GemOx.
  • The study enrolled patients with high-grade B-cell lymphoma, follicular lymphoma grade 3b, and diffuse large B-cell lymphoma (DLBCL).
  • Disease progression data favored Lunsumio-Polivy in each of the three subgroups, with DLBCL's 62% being the biggest benefit among the three lymphoma types.
  • The treatment effect looked similar for patients who received just one prior line of therapy versus at least two.
  • Treatment-related grade 3 or 4 adverse events were similar, at 52.6% and 51.6%, for Lunsumio-Polivy and R-GemOx, respectively.
  • Treatment-related deaths were recorded in 1.5% and 3.1% of patients in the groups, respectively.
  • The Sunmo study's lead author, Jason Westin, M.D., mentioned that the off-the-shelf treatment combination of Lunsumio and Polivy could be administered over a fixed period of time, without mandatory hospitalization or traditional chemotherapy.

Statistics:

  • The Lunsumio-Polivy regimen showed a 59% reduction in the risk of progression or death.
  • The median progression-free survival was 11.5 months for Lunsumio-Polivy, compared to 3.8 months for R-GemOx.
  • The disease progression data favored Lunsumio-Polivy in each of the three subgroups, with DLBCL's 62% being the biggest benefit among the three lymphoma types.
  • The treatment-related grade 3 or 4 adverse events were similar, at 52.6% and 51.6%, for Lunsumio-Polivy and R-GemOx, respectively.
  • Treatment-related deaths were recorded in 1.5% and 3.1% of patients in the groups, respectively.

Sources:

  • "Roche's Lunsumio-Polivy Combination Shows Positive Results in Large B-Cell Lymphoma." (Source: Presented at the International Conference on Malignant Lymphoma)
  • Jason Westin, M.D. (Source: MD Anderson Cancer Center)
  • FDA advisory committee (Source: FDA internal analysis of the Starglo study)
  • European Commission (Source: Clearance of the Columvi regimen in second-line DLBCL)

Read more